Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
RD125
i
Other names:
RD125, CT125A cells, fully human anti-CD5 chimeric antigen receptor T cells, CT125A CAR-T cells, RD-125, RD 125
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
IASO BIO
Drug class:
CD5-targeted CAR-T immunotherapy
Related drugs:
‹
CT125B (0)
MB-105 (0)
CT125B (0)
MB-105 (0)
›
Associations
News
Trials
Filter by
Latest
almost5years
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies (clinicaltrials.gov)
P1, N=18, Not yet recruiting, Huazhong University of Science and Technology
almost 5 years ago
Clinical • New P1 trial • CAR T-Cell Therapy
|
ALK (Anaplastic lymphoma kinase) • CD5 (CD5 Molecule)
|
ALK negative • CD5 positive
|
fludarabine IV • RD125 • cyclophosphamide intravenous
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.